A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

• Status: Completed
• Trial end date: 2021-08-19
• Target enrollment: 0
• Participant gender: Male

Summary

The study was designed as a single-site, randomized, open-label, crossover under fasted conditions. A single oral dose of 0.6 mg Liraglutide injection and Victoza® was given to the 32 healthy Chinese adult male volunteers.Blood samples were collected up to 72 h after administration.The primary pharmacokinetic endpoints were AUC0-t, AUC0-∞, and Cmax. Safety profile and immunogenicity data were collected from each subject.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The Affiliated Hospital of Qingdao University
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Healthy male vulunteers aged 18 and above.

• The body mass index is in the range of 19.0-26.0 kg/m2 (including the critical value).

• Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.

Exclusion Criteria:

• Medical examinations revealed clinically significant abnormalities or any evidence or history of clinically significant disease.

• Volunteers who had used systemic glucocorticoid drugs within 3 months before enrollment.

• Participation in another clinical trial within 3 months.

• Smoking more than 5 cigarettes per day during the 3 months prior to screening.

• Blood donation, massive blood loss (#400mL) or enrolled in other clinical trials 3 months prior to screening.

• Any use of other prescription drugs (including contraceptive)#over-thecounter drugs, Chinese herbal medicine, health care products and 30 days prior to medication for this study.